Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter R Galle, MD
University Medical Center, Mainz, Germany
Study Chair - Richard S Finn, MD
UCLA Department of Medicine, Division of Hematology-Oncology
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucl Saint Luc - Uc Louvain
Brussels, Belgium
- Antwerp University Hospital
Edegem, Belgium
- Chu Amiens-Picardie
Amiens, France
- Hôpital Beaujon - Aphp
Clichy, France
- Hôpital Henri Mondor
Créteil, France
- Jsc Viani Batumi Referral Hospital
Batumi, Georgia
- Israel-Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia
- Universitätsmedizin: Medizinische Klinik Und Poliklinik I
Mainz, Germany
- Humanity and Health Clinical Trial Center
Hong Kong, Hong Kong
- Ospedale Garibaldi Nesima
Catania, Italy
- Institutul Clinic Fundeni
Bucharest, Romania
- Regional Institute of Gastroenterology and Hepatology "dr Octavian Fodor"
Cluj-Napoca, Romania
- Center of Oncology Euroclinic Victoria Hospital
Iași, Romania
- Clinic for Digestive Surgery, University Clinical Center of Serbia
Belgrade, Serbia
- Institue of Oncology Vojvodine Sremska Kamenica (oncology Institute of Volvodina)
Kamenitz, Serbia
- Inje University Haeundae Paik Hospital
Busan, South Korea
- Cha Bundang Medical Center
Seongnam-si, South Korea
- Severance Hospital, Yonsei University Health System
Seoul, South Korea
- Hospital Universitario la Paz
Madrid, Spain
- Hospital Universitario Miguel Servet
Zaragoza, Spain
- National Taiwan University Hospital
Taipei, Taiwan
- Chang Gung Memorial Hospital - Linkou
Taoyuan, Taiwan
- Gazi University Mf
Ankara, Turkey (Türkiye)
- Gülhane Eğitim Ve Araştırma Hastanesi
Ankara, Turkey (Türkiye)
- Koc University Hospital
Istanbul, Turkey (Türkiye)
- Ucla Santa Monica Hematology Oncology
Santa Monica, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Oct 2023
- Primary completion
- 26 Feb 2026
- Completion
- 26 Feb 2026
- Last update posted
- 9 Mar 2026
- Registered enrollment
- 45
- Registry id
- NCT04777851
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.